Skip to main content
×
×
Home

Establishing a dose–response relationship for haloperidol decanoate

  • David Taylor (a1)
Abstract
Aims and Method

The aim of this literature analysis was to establish the range of doses of haloperidol decanoate effective in preventing relapse in schizophrenia. Studies reporting relapse rates in patients treated for longer than 6 months were included. Relapse rate was then plotted against dose or log dose to allow drawing of dose–response curves.

Results

Fifteen publications reporting 13 individual studies were identified. of these, 6 studies met inclusion criteria and were analysed. Dose–response curves indicated limited effect at 25 mg/4 weeks but near maximal effect at doses of 50 mg/4 weeks. There was no clear evidence that increasing the dose above 100 mg/4 weeks provided additional benefit in preventing relapse.

Clinical Implications

The recommended dose range for haloperidol decanoate (50–300 mg/ 4 weeks) does not reflect the findings of this study. Optimally effective doses appear to be around 50–100 mg/4 weeks. The use of doses above 100 mg/4 weeks is difficult to support given data available.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Establishing a dose–response relationship for haloperidol decanoate
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Establishing a dose–response relationship for haloperidol decanoate
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Establishing a dose–response relationship for haloperidol decanoate
      Available formats
      ×
Copyright
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
Hide All
Altamura, A. O., Tacchini, G. I., Maes, M. (1995) Haloperidol plasma ‘threshold’ levels for relapse prevention in schizophrenia: a study with haloperidol decanoate. European Neuropsychopharmacology Supplement, 5558.
Bechelli, L. P. C., Iecco, M. C., Acioli, A., et al (1985) A double-blind trial of haloperidol decanoate and pipothiazine palmitate in the maintenance treatment of schizophrenics in a public out-patient clinic. Current Therapeutic Research, 37, 662671.
British Medical Association And the Royal Pharmaceutical Society of Great Britain (2003) British National Formulary. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain.
Chouinard, G., Annable, L., Campbell, W. (1989) A randomised clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. Journal of Clinical Psychopharmacology, 9, 247253.
Cookson, J. C., Kennedy, N. M. & Gribbon, D. (1986) Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double blind comparative trial of haloperidol decanoate and fluphenazine decanoate. International Clinical Psychopharmacology (suppl1), 4151.
Davis, J. M., Mckane, J. M., Marder, S. R., et al (1993) Dose reponse of prophylactic antipsychotics. Journal of Clinical Psychiatry, 54 (suppl), 2430.
Davis, J. M., Chen, N. & Glick, I. D. (2003) A meta-analysis of the efficacy of second generation antipsychotics. Archives of General Psychiatry, 60, 553564.
Dencker, S. J., Gios, I., Martensson, E., et al (1994) A long term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients. Psychopharmacology, 114, 2430.
Eberhard, G. & Hellborn, E. (1986) Haloperidol decanoate and flupenthixol decanoate in schizophrenia. Acta Psychiatrica Scandinavica, 74, 255262.
Eklund, K. & Forsman, A. (1991) Minimal effective dose and relapse –double blind trial: haloperidol decanoate vs. placebo. Clinical Neuropharmacology, 14, S7S15.
Geddes, J., Freemantle, N., Harrison, P., et al (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ, 321, 13711376.
Hilton, T., Taylor, D. & Abel, K. (1996) Which dose of haloperidol? Psychiatric Bulletin, 20, 359362.
Kane, J. M., Davis, J. M., Schooler, N., et al (2002) A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. American Journal of Psychiatry, 159, 554560.
Koskinen, T., Wistedt, B. & Thelander, S. (1991) Zuclopenthixol decanoate vs. haloperidol decanoate: A double blind comparative study. Biological Psychiatry, 1, 563565.
Mckane, J. P., Robinson, A. D.T., Wiles, D. H., et al (1987) Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenia in-patients. British Journal of Psychiatry, 151, 333336.
Meyerowitz, W., Jaramillo, J. D. C., Denson, D., et al (1989) Optimum therapeutic dosing with haloperidol decanoate. Current Therapeutic Research, 46, 11741178.
Quraishi, S. & David, A. (2000) Depot haloperidol decanoate for schizophrenia (Cochrane Review). In: The Cochrane Library, issue 4. Chichester, UK: John Wiley & Sons, Ltd.
Stone, C. K., Garver, D. L., Griffith, J., et al (1995) Further evidence of a dose–response threshold for haloperidol in psychosis. American Journal of Psychiatry, 152, 12101212.
Tauscher, J. & Kapur, S. (2001) Choosing the right dose of antipsychotics in schizophrenia. CNS Drugs, 15, 671678.
Taylor, D. (1999) Depot antipsychotics revisited. Psychiatric Bulletin, 23, 551553.
Taylor, D. (2000) Low dose typical antipsychotics – a brief evaluation. Psychiatric Bulletin, 24, 465468.
van Putten, T., Marder, S. R. & Mintz, J. (1990) A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Archives of General Psychiatry, 47, 754758.
Wistedt, B. (1984) A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients. International Clinical Psychopharmacology, 1 (suppl 1), 1523.
Wistedt, B., Petsson, T. & Hellborn, E. (1984) A clinical double-blind comparison between haloperidol decanoate and fluphenazine decanoate. Current Therapeutic Research, 35, 804814.
Wistedt, B., Koskinen, T., Thelander, S., et al (1991) Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia; a double blind multicentre study. Acta Psychiatrica Scandinavica, 84, 1416.
Zissi, N. P., Psaras, M. & Kyketsos, G. (1982) Haloperidol decanoate, a new long-acting antipsychotic in chronic schizophrenia: a double blind comparison with placebo. Current Therapeutic Research, 31, 650655.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Bulletin
  • ISSN: 0955-6036
  • EISSN: 1472-1473
  • URL: /core/journals/bjpsych-bulletin
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 1
Total number of PDF views: 11 *
Loading metrics...

Abstract views

Total abstract views: 83 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 17th July 2018. This data will be updated every 24 hours.

Establishing a dose–response relationship for haloperidol decanoate

  • David Taylor (a1)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *